Personalized mRNA treatment reduces melanoma recurrence in landmark Phase 3 trial

Serious thinking male clinical researcher working with microscope inside laboratory, sitting next to another male clinical researcher working on sample with microscope. Female clinical researcher is in the lab observing.

Inova Schar Cancer was among the trial’s leading-enrolling sites, with participation led by principal investigator Dr. Sekwon Jang. A personalized mRNA-based treatment reduced the risk of melanoma returning or causing death by 42% when added to the immunotherapy Keytruda, according to Phase 3 results presented at the 2026 European Society for Medical Oncology Congress.  The…

Read More